Clinical Trial Update: Olaparib in Patients With HRD Malignant Mesothelioma [Phase 2]

View source ↗

Summary

Olaparib is being evaluated in a Phase 2 trial for patients with malignant mesothelioma exhibiting homologous recombination deficiency; the study is currently r…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malignant Mesothelioma

Drugs mentioned

• Olaparib (Olaparib)

Snippet

Sponsor: University of Chicago | Conditions: Mesothelioma, Homologous Recombination Deficiency | Phase 2 | Status: RECRUITING